Literature DB >> 15735959

Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide.

Fuyi Wang1, Juraj Bella, John A Parkinson, Peter J Sadler.   

Abstract

The ruthenium arene anticancer complex [(eta(6)-bip)Ru(en)Cl][PF(6)] (1) (bip is biphenyl, en is ethylenediamine) reacted slowly with the amino acid L-histidine (L-His) in aqueous solution at 310 K. Two L-His adducts of 1 were separated by high-performance liquid chromatography and identified by electrospray ionisation mass spectrometry and NMR: an imidazole N(delta)-bound complex [(eta(6)-bip)Ru(en)(N(delta)-L-His)](2+), and an N(epsilon)-bound complex [(eta(6)-bip)Ru(en)(N(epsilon)-L-His)](2+). At 310 K, after 24 h only about 22% of complex 1 (2 mM) reacted with L-His, and of the unreacted 1, 59% had hydrolysed. In the presence of 100 mM NaCl, approximately 90% of 1 remained unreacted. In aqueous solution or triethylammonium acetate (TEAA) buffer (pH 7.6), (15)N-labelled 1 reacted with cytochrome c to give two monoruthenated protein adducts. The reaction reached equilibrium within 2 h by which time approximately 50% of cytochrome c was ruthenated. On the basis of [(1)H, (15)N] NMR data, one adduct may have Ru bound to the N-terminus, and the other to a carboxylate group on the protein. In TEAA buffer and at 310 K, more than 90% of the 14-mer oligonucleotide d(TATGTACCATGTAT) reacted with 2 mol Eq of 1 to give rise to monoruthenated and diruthenated oligonucleotide adducts. The presence of cytochrome c (1 mol Eq) or L-His (4 mol Eq) had little effect on the course of the reaction with the oligonucleotide. In cells, DNA (or RNA) may be a favoured reaction site for this Ru anticancer complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735959     DOI: 10.1007/s00775-004-0621-5

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  14 in total

1.  Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell?

Authors:  J Reedijk
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  The electronic structure and spectra of Ru(II) and Ru(III) complexes with imidazole and its derivatives.

Authors:  I V Rogachevsky; V I Baranovski
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2000-12       Impact factor: 4.098

3.  High-resolution three-dimensional structure of horse heart cytochrome c.

Authors:  G W Bushnell; G V Louie; G D Brayer
Journal:  J Mol Biol       Date:  1990-07-20       Impact factor: 5.469

4.  The protein-folding speed limit: intrachain diffusion times set by electron-transfer rates in denatured Ru(NH3)5(His-33)-Zn-cytochrome c.

Authors:  I-Jy Chang; Jennifer C Lee; Jay R Winkler; Harry B Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

5.  Inhibition of cancer cell growth by ruthenium(II) arene complexes.

Authors:  R E Morris; R E Aird; P del S Murdoch; H Chen; J Cummings; N D Hughes; S Parsons; A Parkin; G Boyd; D I Jodrell; P J Sadler
Journal:  J Med Chem       Date:  2001-10-25       Impact factor: 7.446

6.  The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.

Authors:  F Kratz; M Hartmann; B Keppler; L Messori
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

7.  Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.

Authors:  Fuyi Wang; Haimei Chen; Simon Parsons; Iain D H Oswald; James E Davidson; Peter J Sadler
Journal:  Chemistry       Date:  2003-12-05       Impact factor: 5.236

8.  Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

Authors:  Haimei Chen; John A Parkinson; Robert E Morris; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2003-01-08       Impact factor: 15.419

9.  A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients.

Authors:  J Schleucher; M Schwendinger; M Sattler; P Schmidt; O Schedletzky; S J Glaser; O W Sørensen; C Griesinger
Journal:  J Biomol NMR       Date:  1994-03       Impact factor: 2.835

10.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.

Authors:  R E Aird; J Cummings; A A Ritchie; M Muir; R E Morris; H Chen; P J Sadler; D I Jodrell
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more
  24 in total

1.  Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.

Authors:  Rebecca H Wills; Abraha Habtemariam; Andrea F Lopez-Clavijo; Mark P Barrow; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-01       Impact factor: 3.109

2.  In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen.

Authors:  Miljana Momcilovic; Thomas Eichhorn; Jana Blazevski; Harry Schmidt; Goran N Kaluđerović; Stanislava Stosic-Grujicic
Journal:  J Biol Inorg Chem       Date:  2015-02-10       Impact factor: 3.358

3.  The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Authors:  Dragana Stanic-Vucinic; Stefan Nikolic; Katarina Vlajic; Mirjana Radomirovic; Jelena Mihailovic; Tanja Cirkovic Velickovic; Sanja Grguric-Sipka
Journal:  J Biol Inorg Chem       Date:  2020-02-04       Impact factor: 3.358

4.  Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.

Authors:  Fuyi Wang; Abraha Habtemariam; Erwin P L van der Geer; Rafael Fernández; Michael Melchart; Robert J Deeth; Rhona Aird; Sylvie Guichard; Francesca P A Fabbiani; Patricia Lozano-Casal; Iain D H Oswald; Duncan I Jodrell; Simon Parsons; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

5.  Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity.

Authors:  Anna Rathgeb; Andreas Böhm; Maria S Novak; Anatolie Gavriluta; Orsolya Dömötör; Jean Bernard Tommasino; Eva A Enyedy; Sergiu Shova; Samuel Meier; Michael A Jakupec; Dominique Luneau; Vladimir B Arion
Journal:  Inorg Chem       Date:  2014-02-20       Impact factor: 5.165

6.  Growth Inhibitory Activity of a Bis-benzimidazole-Bridged Arene Ruthenium Metalla-Rectangle and Prism.

Authors:  Vaishali Vajpayee; Sun Mi Lee; Joeng Woo Park; Abhishek Dubey; Hyunuk Kim; Timothy R Cook; Peter J Stang; Ki-Whan Chi
Journal:  Organometallics       Date:  2013-03-25       Impact factor: 3.876

Review 7.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

8.  Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.

Authors:  Kui Wu; Wenbing Hu; Qun Luo; Xianchan Li; Shaoxiang Xiong; Peter J Sadler; Fuyi Wang
Journal:  J Am Soc Mass Spectrom       Date:  2013-02-13       Impact factor: 3.109

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

10.  Identification of (eta6-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta6-p-cymene)RuCl2 (DMSO)] to stress-regulated proteins and to helicases.

Authors:  Joanna Will; Andreas Kyas; William S Sheldrick; Dirk Wolters
Journal:  J Biol Inorg Chem       Date:  2007-05-22       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.